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Abstract
Epithelial ovarian cancer is the most lethal gynecologic malignancy. In most women, it is diagnosed at an advanced
stage, which largely explains the poor prognosis of this malignancy. Germline mutations of the genes BRCA1 and
BRCA2, which encode proteins essential for the repair of double-strand DNA breaks through homologous
recombination, lead to increased cancer predisposition. BRCA mutations are present in approximately 14% of
epithelial ovarian cancers. Somatic BRCA mutations have also been described. Current first-line treatment of high-
grade epithelial ovarian cancer includes debulking surgery followed by combination chemotherapy, usually
carboplatin and paclitaxel. Ovarian cancer is highly sensitive to chemotherapy, in particular to platinum drugs. Most
patient will achieve remission with initial chemotherapy, but most will eventually experience disease recurrence.
Targeted therapies, including the anti-angiogenic agent bevacizumab and oral poly (ADP-ribose) polymerase (PARP)
inhibitors, have been recently approved for the treatment of ovarian cancer, based on the results from randomized
clinical trials showing significant benefits in terms of progression-free survival, with acceptable tolerability and no
detrimental effects on quality of life. Olaparib, the first PARP inhibitor to be granted approval, is currently indicated
as maintenance monotherapy in ovarian cancer patients with relapsed disease and mutated BRCA who have
achieved a complete or partial response to platinum-based chemotherapy. The analysis of BRCA mutational status
has, therefore, also become crucial for therapeutic decisions. Such advances are making personalized treatment of
ovarian cancer feasible. Here we briefly review treatments for platinum-sensitive, high-grade serous epithelial
ovarian cancer that are currently available in Italy, with a focus on targeted therapies and the relevance of BRCA
mutational analysis. Based on the evidence and on current guidelines, we propose strategies for the tailored
treatment of patients with relapsed ovarian cancer that take into account BRCA mutational status and the treatment
received in the first-line setting.
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Introduction
Epithelial ovarian cancer is the most lethal gynecologic
malignancy [1]. In most patients, ovarian cancer is diag-
nosed when the disease has progressed to an advanced
stage, corresponding to stages IIb to IV of the Inter-
national Federation of Gynecology and Obstetrics
(FIGO) classification, with the involvement of the peri-
toneal cavity and other organs [2]. This largely explains
the poor prognosis of this malignancy.
Epithelial ovarian cancer, which accounts for 90% of
primary ovarian tumors, is a heterogeneous disease com-
prising several histologic subtypes: serous, mucinous,
endometrioid, clear cell, transitional cell (Brenner
tumors), mixed, and undifferentiated type [2]. The car-
cinogenesis of epithelial ovarian cancer is not fully eluci-
dated. According to a dualistic model of carcinogenesis,
ovarian cancer can be divided into two broad categories,
type I and type II [3]. Type I tumors include low-grade
serous, mucinous, endometrioid and clear cell carcin-
omas, and Brenner tumors; they are generally indolent
and characterized by mutations of genes involved in sig-
naling pathways (KRAS, BRAF, PTEN, PIK3CA,
CTNNB1, ARID1A, and PPP2R1A) [3]. Type II tumors
are the most prevalent category and include high-grade
serous, endometrioid, and undifferentiated carcinomas;
they are aggressive, genetically highly unstable, and are
usually diagnosed at an advanced stage [3]. Type II
tumors rarely harbor the mutations detected in type I
tumors, while mutations of p53 and BRCA are common
[3, 4]. Mutations of the genes BRCA1 and BRCA2 lead
to increased cancer predisposition and are present in
approximately 14% of epithelial ovarian cancers, accord-
ing to recent population-based studies [5]. BRCA1 and
BRCA2 encode proteins that play an essential role in the
repair of double-strand DNA breaks through homolo-
gous recombination. Somatic BRCA mutations and epi-
genetic inactivation of these genes have been implicated
in sporadic ovarian cancer [6, 7].
Low-grade epithelial ovarian cancer, with disease con-
fined to the ovaries and pelvis (FIGO stages I-IIa), is
treated with surgical resection (debulking surgery) [8].
In 70% of the cases, this intervention is curative, while
30% are at risk of recurrence [8]. Current first-line treat-
ment of high-grade epithelial ovarian cancer (FIGO
stages IIb-IV) includes debulking surgery followed by
combination chemotherapy, usually carboplatin and pac-
litaxel [8]. Ovarian cancer is highly sensitive to chemo-
therapy drugs, in particular to platinum. While most
patient will achieve remission with initial chemotherapy,
most will eventually experience disease recurrence [2, 9].
Chemotherapy for relapsed high-grade ovarian cancer
includes platinum-based combination regimens for
patients with disease recurrence more than 6–12months
after the completion of first-line chemotherapy, and
sequential single cytotoxic agents for those with disease
recurrence earlier than 6months after completion of ini-
tial chemotherapy [2].
The treatment armamentarium has been recently ex-
panded by the addition of targeted therapies, including
bevacizumab, a humanized monoclonal antibody against
vascular endothelial growth factor (VEGF), and oral in-
hibitors of poly (ADP-ribose) polymerase (PARP). With
regard to epithelial ovarian cancer, bevacizumab is
licensed: i) in combination with carboplatin-paclitaxel,
for the front-line treatment of stage IIIB, IIIC and IV
cancer; ii) in combination with carboplatin-gemcitabine,
for the treatment of the first recurrence of
platinum-sensitive cancer not previously treated with
anti-angiogenic therapies; iii) in combination with pacli-
taxel, topotecan, or pegylated liposomal doxorubicin
(PLD), for the treatment of platinum-resistant relapsed
cancer, after no more than two prior chemotherapy regi-
mens, and not previously treated with anti-angiogenic
therapies [10]. Olaparib, the first PARP inhibitor to be
granted marketing authorization (in 2014), is licensed in
the European Union (EU) as monotherapy for the main-
tenance treatment of patients with platinum-sensitive
relapsed BRCA-mutated (germline and/or somatic)
high-grade serous epithelial ovarian cancer who are in
complete or partial response to platinum-based
chemotherapy [11].
The introduction of targeted drugs has significantly in-
creased treatment options and contributed to the develop-
ment of individualized strategies. BRCA mutational analysis
has become essential for making therapeutic decisions. In
this review, we discuss first- and second-line treatment
options currently available in Italy for high-grade serous
epithelial ovarian cancer, with a focus on the most relevant
findings concerning targeted therapies. We also briefly
review the main data highlighting the importance of BRCA
mutational analysis in the management of patients with
ovarian cancer. Based on the reviewed evidence and on
current guidelines we propose treatment algorithms for
patients with relapsing high-grade, platinum-sensitive
ovarian cancer that take into account BRCA mutational
status and previous exposure to targeted therapies.
Treatment of high-grade serous epithelial ovarian
cancer
Surgery
Debulking or cytoreductive surgery has a double role in the
management of high-grade ovarian cancer because it is not
only used for diagnosis and staging, but also as a thera-
peutic intervention [2]. The goal of primary debulking sur-
gery is to remove all visible disease. The amount of residual
disease is an independent prognostic factor of survival, and
the absence of macroscopic residual disease is associated
with a significantly lower risk of recurrence [8]. Patients
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not eligible for debulking surgery may benefit from neoad-
juvant chemotherapy [12]. Preliminary data from a phase
III trial suggest that surgery can be repeated with benefits
in highly selected patients with platinum-sensitive disease:
in the AGO DESKTOP III/ENGOT ov20 trial, secondary
cytoreductive surgery was associated with a clinically
meaningful 5.6-month increase of progression-free survival
(PFS) [13].
Evidence for the role of hyperthermic intraperitoneal
chemotherapy (HIPEC) after cytoreductive surgery up-
front are limited. After interval debulking surgery and
in the recurrent setting, in a phase III trial that in-
cluded 245 women who had at least stable disease
after three cycles of neoadjuvant chemotherapy with
carboplatin plus paclitaxel, the patients who under-
went cytoreductive surgery with HIPEC experienced a
significantly longer recurrence-free survival (hazard
ratio [HR] 0.66; 95% CI, 0.50–0.87) and overall sur-
vival (OS) (HR: 0.67; 95% CI, 0.48–0.94) compared to
those who underwent cytoreductive surgery alone
[14]. The rate of severe adverse events was similar in
the two groups. In this context, HIPEC should be
performed in clinical trials or in referral centers with
high experience in ovarian cancer management.
First-line chemotherapy
The combination of carboplatin area-under-the-curve
(AUC) 5 and paclitaxel (175 mg/m2 intravenously over 3
h, every 21 days) remains the standard approach in the
first-line setting, despite disappointing results from the
long-term follow-up of the registration studies showing
relapse rates of 70–80% within the first 2 years [8]. Alter-
natives to this approach have been extensively studied
over the past two decades, but no chemotherapeutic
regimen has been conclusively demonstrated as superior
to the standard carboplatin-paclitaxel combination [8,
15–18]. Acceptable alternatives include weekly paclitaxel
plus every-3-week carboplatin, the addition of bevacizu-
mab to 3-weekly carboplatin-paclitaxel, and intraperito-
neal therapy [8, 16, 17].
The recent results of the SOLO-1 trial could define a
new standard in first line treatment for women diag-
nosed with advanced ovarian cancer who carry a BRCA
1/2 mutation. SOLO-1 is the first, double-blind, rando-
mised, prospective phase III trial evaluating front line
olaparib maintenance therapy after platinum-based
chemotherapy in newly diagnosed advanced ovarian can-
cer (FIGO stage III–IV) with a BRCA mutation [18]. A
total of 391 patients with high grade serous or endome-
trioid ovarian cancer who were in clinical complete or
partial response after chemotherapy upon entering the
study were randomised 2:1 to olaparib tablets 300 mg bd
(n = 260) or placebo (n = 131) for two years. The pri-
mary endpoint was investigator-assessed PFS from
randomisation. Secondary outcomes included PFS2
(time from randomisation to the second progression),
OS and quality of life. Median follow-up was 41 months.
PFS2 remained significantly improved among patients
who had received olaparib maintenance, with a median
PFS2 of 41.9 months for placebo versus median not
reached for the olaparib group (HR: 0.50; 95% CI, 0.35–
0.72; P = 0.0002). There was no clinically relevant
change in quality of life between groups and dosing was
well tolerated, with only 12% of patients discontinuing
olaparib, due to toxicity and not disease progression [18].
Second-line chemotherapy
Treatment of relapsing ovarian cancer is curative only in
a minority of patients. The goals of second-line treat-
ment are to prolong survival, to postpone symptomatic
disease progression, and to improve quality of life.
Serous histotype, the presence of BRCA mutations,
tumor size, and the number of metastases are independ-
ent predictive factors of response to second-line chemo-
therapy. A crucial issue in relapsing patients is when to
initiate second-line treatment. Evidence suggests that
early second-line treatment initiation, prompted by bio-
chemical relapse (i.e., increased level of cancer antigen
[CA] 125), is not beneficial [19].
Various options for second-line treatment of re-
lapsed ovarian cancer are available. Treatment choice
has traditionally been guided by the sensitivity to
platinum-based therapy. Patients sensitive or partially
sensitive to platinum, defined respectively by a
platinum-free-interval (PFI) > 12 or by a PFI of 6–12
months, are treated with combination chemotherapy,
usually platinum-based [8]. A non-platinum option –
trabectedin plus PLD – has obtained good results in
terms of PFS and OS, and the phase III INOVAT-
YON trial (NCT01379989) is currently comparing this
regimen versus the combination of carboplatin plus
PLD in this setting [20]. Few second-line options are
available for patients resistant to platinum, but the
introduction of targeted therapies may improve out-
comes also in this difficult-to-treat subgroup.
Targeted therapies
Anti-angiogenic agents
Bevacizumab in combination with chemotherapy has
been extensively investigated in various settings of ovar-
ian cancer treatment, including first-line treatment
(GOG-0218, ICON7 studies) [21, 22], and treatment of
recurrent ovarian cancer in platinum-sensitive patients
(OCEANS study) [23, 24], and in platinum-resistant
patients (AURELIA study) [25]. Overall, the addition of
bevacizumab to chemotherapy has been shown to pro-
long PFS, with an acceptable tolerability profile and pre-
served quality of life. In the GOG-0218 study, for
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example, 1873 women with stage III or IV epithelial
ovarian cancer who had undergone debulking surgery
were randomized to one of three treatments [21]. All
three treatments included 6 cycles of standard front-line
chemotherapy (carboplatin-paclitaxel). The control treat-
ment was chemotherapy plus placebo added in cycles 2
through 22; bevacizumab-initiation treatment was
chemotherapy plus bevacizumab (15 mg per kg of body
weight, every 3 weeks) added in cycles 2 through 6 and
placebo added in cycles 7 to 22; bevacizumab-throughout
treatment was chemotherapy plus bevacizumab added in
cycles 2 through 22. The median PFS was 10.3months in
the control group, compared with 11.2months in the
bevacizumab-initiation group and 14.1months in the bev-
acizumab-throughout group. Relative to the control
treatment, the hazard ratio for progression or death
was 0.717 (95% CI, 0.625–0.824; P < 0.001) with
bevacizumab-throughout. The difference in PFS
between the control group and the bevacizumab-initi-
ation group was not significant, which implies that
bevacizumab treatment must be continued beyond
chemotherapy to delay disease progression. There was
no significant difference in OS among the three
groups. The addition of bevacizumab was associated
with more adverse events (hypertension and gastro-
intestinal toxicity), but the rates of gastrointestinal
events remained below 3%. No decline in quality of
life was reported.
In the OCEANS study that included 484 patients with
platinum-sensitive relapsed epithelial ovarian, primary
peritoneal, or fallopian tube cancer, median PFS was
12.4 months with bevacizumab (15 mg/kg) added to
carboplatin-gemcitabine and 8.4 months in the group
treated with chemotherapy alone (HR: 0.484; 95% CI,
0.388–0.605; P < 0.001) [23]. Results from the final OS
analysis showed no significant difference in OS between
patients treated with carboplatin-gemcitabine plus beva-
cizumab (median OS, 33.6 months) and those treated
with chemotherapy alone (32.9 months) [24]. Median
follow-up was 58.2 months in the bevacizumab group
and 56.4 months in the placebo group. No unexpected
safety issues were reported following prolonged exposure
to bevacizumab.
The guidelines for ovarian cancer treatment revised in
2017 by the Italian Association of Medical Oncology
(AIOM) recommend considering six cycles of bevacizu-
mab in combination with carboplatin-paclitaxel, followed
by maintenance monotherapy for the first-line treat-
ment of women with high-grade ovarian carcinoma
after both optimal (weak recommendation) and
non-optimal (strong recommendation) debulking sur-
gery [8]. In the second-line setting, bevacizumab can
be considered in those patients who have not been
previously treated with it [8].
PARP inhibitors
Repair of DNA damage is essential for the maintenance
of genomic integrity. The proteins encoded by the
BRCA1 and BRCA2 genes are involved in the repair of
double-strand DNA breaks. The loss of function of these
genes, commonly associated with ovarian cancer, makes
cancer cells more dependent on alternative DNA repair
processes such as single-strand DNA repair. PARP is an
essential component of single-strand DNA repair, and its
inhibition prevents cancer cells with deficient BRCA
function from repairing chemotherapy-induced DNA
damage, making them more vulnerable to cytotoxic
agents, a concept known in oncology as synthetic lethal-
ity [26, 27].
The efficacy of olaparib as maintenance therapy has
been demonstrated in randomized, double-blind,
placebo-controlled, phase II (Study 19) and phase III
(SOLO 2/ENGOT-Ov21) trials [28–30]. In Study 19,
conducted in 265 patients with platinum-sensitive, re-
lapsed, high-grade serous ovarian cancer, monotherapy
with olaparib 400mg twice daily (oral capsule formula-
tion) was associated with a significantly longer median
PFS compared with placebo (8.4 months versus 4.8
months; HR for progression or death, 0.35; 95% CI,
0.25–0.49; P < 0.001) [28]. No significant difference
between groups was seen in OS. Adverse events more
frequently reported in the group treated with olaparib
included nausea, fatigue, vomiting, and anemia, which
were mostly of grade 1 or 2. A preplanned analysis of
Study 19 data by BRCA mutation status showed that
patients with platinum-sensitive relapsed serous ovarian
cancer with a BRCA mutation were more likely to bene-
fit from treatment with olaparib [29]. In the BRCA-mu-
tated group, median PFS was 11.2 months in patients
treated with olaparib and 4.3 months in those receiving
placebo (HR: 0.18; 95% CI, 0.10–0.31; P < 0.0001).
Median time to first subsequent therapy or death
(TFST) and median time to second subsequent therapy
or death (TSST) were also analyzed and were, respect-
ively, 15.6 months (olaparib) versus 6.2 months (placebo)
(HR: 0.33; 95% CI, 0.22–0.50; P < 0.0001), and 23.8
months versus 15.2 months (HR: 0.44; 95% CI, 0.29–
0.67; P = 0.00013) in patients with a BRCA mutation. A
final OS analysis following the death of 203 (77%) of the
265 patients in Study 19, after more than 5 years of
follow-up, revealed a longer OS of BRCA-mutated
patients receiving olaparib maintenance therapy, but the
differences between groups did not reach statistical sig-
nificance [30]. The long-term exposure to olaparib was
not associated with unexpected safety reports. The effi-
cacy of olaparib (300 mg, twice daily, tablet formulation)
as maintenance therapy has been further confirmed in
the SOLO 2/ENGOT-Ov21 trial including 295 patients
with platinum-sensitive, relapsed BRCA-mutated ovarian
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cancer, who had received at least two lines of previous
chemotherapy [31]. Based on the data from the Study 19
and SOLO 2/ENGOT-Ov21 trial, the 2017 AIOM Italian
guidelines for the treatment of ovarian carcinoma
state that olaparib can be considered following
chemotherapy as maintenance therapy in women with
BRCA mutations [8].
Two additional PARP inhibitors will be available soon:
niraparib, approved by the European Medicines Agency
(EMA) in November 2017, and rucaparib (EMA
approval procedure is ongoing). Niraparib was evaluated
in the phase III ENGOT-OV16/NOVA trial in 553
women with platinum-sensitive, recurrent ovarian can-
cer and was shown to improve PFS substantially and sig-
nificantly versus placebo, regardless of the presence or
absence of germline BRCA mutations or homologous re-
combination deficiency (HRD)-status, extending the
potential of PARP inhibition beyond BRCA-mutated
cancers [32]. Rucaparib was also evaluated in trials in
which patients were categorized according to the pres-
ence or absence of BRCA mutations and to HRD-status
[33, 34]. In the phase III ARIEL 3 trial, rucaparib signifi-
cantly improved PFS over placebo in ovarian cancer
patients who had achieved a response to platinum-based
chemotherapy, regardless of BRCA mutational status or
HRD status [33]. Overall, these findings provide further
support to the potential of PARP inhibition in the main-
tenance setting. With regard to the selection of the most
appropriate therapy, diagnostic companion testing and
resource availability will likely play a central role.
Analysis of BRCA mutational status
Germline BRCA mutational status evaluation is recom-
mended for all women diagnosed with nonmucinous,
non-borderline, epithelial ovarian, fallopian tube, or pri-
mary peritoneal cancer [35]. The goals of genetic testing
include completing the diagnostic procedure, guiding
therapeutic decisions, and making prevention possible in
first-grade relatives of ovarian cancer patients [35]. A
positive test in unaffected female relatives may indeed lead
to more accurate and frequent monitoring, prophylactic
mastectomy, and prophylactic salpingo-oophorectomy
with well-established benefits in terms of reduced risk of
incident ovarian, fallopian tube and peritoneal cancer [36].
A positive genetic test has important implications also for
affected patients because the prognosis is significantly
more favorable in patients with mutated BRCA
(m-BRCA), and the presence of BRCA mutations is pre-
dictive of drug sensitivity to therapeutic combinations
with platinum and to PARP inhibitors [36]. Validated pro-
cedures for germline mutation testing in peripheral blood
are available, while the identification of somatic BRCA
mutations in tumors is more complex and still sub-
optimal [37].
Data from the Cancer Genome Atlas (TCGA) have
demonstrated that approximately 50% of high-grade ser-
ous ovarian cancers are characterized by HRD and sug-
gested that the homologous recombination pathway for
DNA repair is not only disrupted by germline and som-
atic BRCA mutations but also by mutations in other
genes [38, 39]. This trait of altered DNA repair mecha-
nisms is also known in the literature as “BRCAness,” to
indicate the similarity with traits occurring in cancers
harboring BRCA mutations. Validated procedures for
testing HRD and identifying other mutated genes are
needed to further select subgroups of patients likely to
benefit from novel treatments. Notably, the ARIEL2
study with rucaparib has evaluated the ability of tumor
genomic loss of heterogeneity (LOH) to predict response
to PARP inhibition, based on the hypothesis that, along
with BRCA mutations, LOH may represent HRD [34].
The results suggest that LOH may be used to identify
patients with wild-type BRCA (wt-BRCA) who can bene-
fit from treatment with a PARP inhibitor [34].
Algorithm for the treatment of platinum-sensitive
relapsed epithelial ovarian cancer
The strategy we suggest for the treatment of patients
with relapsed, platinum-sensitive ovarian cancer is
tailored to patients based on whether they have been
treated with bevacizumab in the first-line setting and on
their BRCA mutational status (Figs. 1 and 2).
In our clinical practice bevacizumab is generally used
in combination with carboplatin-paclitaxel in the
first-line setting, unless contraindicated. Typical contra-
indications for the use of bevacizumab are the complica-
tions associated with major abdominal surgical
procedures. As recommended by current guidelines,
bevacizumab can be used regardless of the presence of
residual disease following debulking surgery [8]. The evi-
dence supporting this approach is, however, stronger in
patients with suboptimal debulking surgery [8]. Further
evidence about the efficacy and safety of bevacizumab in
this setting will hopefully be provided by further re-
search, including the ongoing trial MITO16-MANGO2
(NCT01706120). This trial is investigating potential clin-
ical and biological prognostic factors in ovarian cancer
patients receiving a combination of bevacizumab and
carboplatin-paclitaxel as first-line treatment.
Decisions concerning maintenance therapy in
platinum-sensitive disease are currently made based on
BRCA mutational status. BRCA mutational status is the
first defined predictive marker guiding therapeutic deci-
sions in ovarian cancer, In our practice, olaparib is the
targeted therapy of choice for maintenance treatment in
patients with m-BRCA who have achieved a partial or
complete response to second-line platinum-based
chemotherapy (Fig. 1) [11]. BRCA-mutated patients not
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previously treated with bevacizumab, and with no con-
traindications to anti-angiogenic therapy, can be offered
the option of treatment with bevacizumab in the
second-line setting, before considering olaparib (Fig. 1).
According to the results from the OCEANS trial, pa-
tients with very high disease burden (e.g., patients pre-
senting with ascites and/or pleural effusion), who have
not received bevacizumab in combination with
chemotherapy as first-line, may still benefit from the
addition of bevacizumab to second-line chemotherapy
[23, 24].
In patients with platinum-sensitive relapsed ovarian
cancer with wt-BRCA, treatment decisions for the
second-line setting also depend on prior exposure to
bevacizumab (Fig. 2). Second-line options include
platinum-based combination chemotherapy for those
Fig. 1 Algorithm for the treatment of patients with recurrent platinum-sensitive, epithelial ovarian cancer and m-BRCA. PARP-I, PARP inhibitor;
PLD, pegylated liposomal doxorubicin
Fig. 2 Algorithm for the treatment of patients with recurrent platinum-sensitive, epithelial ovarian cancer and wt-BRCA. PARP-I, PARP inhibitor;
PLD, pegylated liposomal doxorubicin; PFI, platinum-free interval
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patients who have already been treated with bevacizu-
mab in the first-line setting. For patients not previously
treated with bevacizumab, second-line options include
the addition of bevacizumab to the combination carbo-
platin-gemcitabine according to the EMA indication,
or a platinum-based combination without the addition
of bevacizumab if this agent is contraindicated [10].
Conclusions and future perspectives
The recent addition of targeted therapies –
anti-angiogenic agents and PARP inhibitors – to the
pharmacologic treatments available for ovarian cancer
has improved patient outcomes while increasing the
available options for the traditionally difficult-to-treat
disease. The correct sequence of treatments, including
the decision of adding bevacizumab to the first- or
second-line treatment, is mainly based on clinical fac-
tors. The analysis of BRCA mutational status has
allowed the first step into individualized strategies for
the management of patients with ovarian cancer. This
analysis remains crucial and should be offered routinely
at the time of diagnosis to all patients. The development
of new PARP inhibitors, which also have proven effective
in patients with wt-BRCA, and the advances in our
understanding of HRD will further improve patient se-
lection and extend the usefulness of targeted therapies
for ovarian cancer. In this respect, ongoing trials of par-
ticular interest are those investigating PARP inhibitors in
patients with mutations in homologous recombination
repair-associated genes (e.g., NCT02354131 and
NCT02655016). Other interesting ongoing lines of re-
search are addressing the combination of targeted ther-
apies (e.g., anti-angiogenic agents with PARP inhibitors)
[40, 41]. We also need to understand the long-term tol-
erability of the various PARP inhibitors, whether they
have distinct safety profiles, and the mechanisms leading
to the development of resistance. Future studies should
focus on the optimization of tolerability and the assess-
ment of patient-reported outcomes including quality of
life to improve our understanding of the effects of
prolonged maintenance treatment with targeted therap-
ies compared to those of intermittent chemotherapy.
Finally, considering the results of SOLO-1 trial, future
studies should clarify the role of PARP inhibitors main-
tenance after previous PARP inhibitors exposure.
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